The Cancer Chemotherapy Handbook

DAVID S. FISCHER, M.D., F.A.C.P.
Clinical Professor of Medicine
Yale University School of Medicine
Attending Physician
Yale New Haven Hospital
Hospital of St. Raphael
New Haven, Connecticut

M. TISH KNOBF, R.N., M.S.N.
Clinical Nurse Specialist
Head Nurse, Medical Oncology
Outpatient Center
Yale University School of Medicine
Yale New Haven Hospital
New Haven, Connecticut

YEAR BOOK MEDICAL PUBLISHERS, INC.
Chicago • London • Boca Raton • Littleton, Mass.
Contents

Foreword v
Preface to the Third Edition vii
Preface to the First Edition ix

PART I CHEMOTHERAPY OF CANCER 1

Etiology of Cancer 1
Cancer Chemotherapy 2

1/ Cancer Chemotherapy 3
The Nature of Cancer 3
Cell Cycle 4
Classification of Cancer Chemotherapeutic Drugs 5
Drugs Presented 11
Toxicity 12
Cancer Chemotherapeutic Agents 16

2/ Delivery of Cancer Chemotherapy 199
Dose Calculations 199
Intravenous Drug Administration 200
Central Venous Catheters 205
Ambulatory Infusion Pumps for Drug Delivery 211
Intra-Arterial Drug Administration 216
Central Nervous System Drug Delivery 220
Intraperitoneal Chemotherapy 223
Other Approaches to Chemotherapy Drug Delivery 233
Handling of Antineoplastic Agents 233

3 / Clinical Trials 248
Physician Participation in Clinical Trials 249
Efforts of the National Cancer Institute 250
Phases of Clinical Trials 251
National Cancer Institute Drug Development Program and Drug Procurement 258

4 / Combination Chemotherapy 261
Adrenal Cortical Carcinoma 267
Bladder Carcinoma 268
Brain Tumors 271
Breast Carcinoma 272
Carcinoid 282
Cervical Carcinoma 284
Colon Carcinoma 287
Endometrial Carcinoma 289
Esophageal Carcinoma 291
Ewing's Sarcoma 293
Gastric Carcinoma 295
Gestational Trophoblastic Disease 296
Head and Neck Carcinoma 299
Leukemia: Acute Lymphoblastic 303
Leukemia: Acute Nonlymphocytic 305
Leukemia: Blastic Chronic Granulocytic 310
Liver Carcinoma 311
Liver Carcinoma: Metastases of Otherwise Controlled Carcinoma 312
Lung Cancer: Non-Small Cell Carcinoma 313
Lung Cancer: Small Cell Carcinoma 317
Lymphoma: Hodgkin's Disease 320
Lymphoma: Non-Hodgkin's Disease 327
Melanoma 338
Mesothelioma 340
Multiple Myeloma 341

Osteosarcoma 346
Ovarian Carcinoma 348
Pancreatic Carcinoma 352
Prostatic Carcinoma 354
Sarcomas 356
Testicular Carcinoma 359
Thymoma 363
Thyroid Carcinoma 364

5 / Biologic Response Modifiers 366
Interferons 367
Interleukin-2 and Lymphokine-Activated Killer Cells 371
Tumor Necrosis Factor 373
Growth Factors 374
Therapeutic Monoclonal Antibodies 374
Diagnostic Monoclonal Antibodies and Tumor Markers 376
Assessment and Management of BRM Toxicity 379

PART II MANAGEMENT OF THE PATIENT AND FAMILY 387

6 / Patient and Family Support Needs 389
Psychosocial Assessment 390
Needs Assessment 393
Strategies for the Health Care Provider 394

7 / Ethical Considerations in Cancer 398
To Tell the Truth 399
“Do Not Resuscitate” Orders 400
Hospice 401
Discontinuing Care 402
Ethics and Clinical Research 403
Ethics Committees and Codes 405

8 / Nutritional Problems and Management 409
Nutritional Problems 409
Dietary Counseling 418
Nutritional Supplementation 422
Hyperalimentation 427

9 / Infection in the Cancer Patient 440
  Pathogenesis of Infection 440
  Prevention or Reduction of Infection in High-Risk Patients 442
  Diagnosis 444
  Therapy 447
  Other Infections 461

10 / Cancer Pain Management 470
  Underestimating Need 470
  Kinds of Pain 473
  Assessment 475
  Using Analgesics for Mild Pain 477
  Using Analgesics for Moderate Pain 480
  Using Analgesics for Severe Pain 481
  Additional Measures for Pain Control 486

11 / Gastrointestinal Toxicity 495
  Nausea, Vomiting, and Antiemetic Therapy 495
  Physiology of Nausea and Vomiting 495
  Chemotherapy-Induced Nausea and Vomiting 496
  Pharmacologic Therapy 502
  Nonpharmacologic Approaches to Nausea and Vomiting 515
  Consequences of Nausea and Vomiting 516
  Interventions 517
  Stomatitis 518

12 / Dermatologic Toxicity 548
  Alopecia 548
  Drugs With Potential for Local Toxicity 557
  Extravasation 558
  Systemic Dermatologic Effects 564
  Enhanced Skin Reactions With Multimodality Therapy 565

13 / Hematologic Toxicity 572
  Anemia 572
  Leukopenia-Granulocytopenia 577
  Thrombocytopenia 583

Index 593